ArticleDiscover oncology2025
METTL3 and METTL14 drive pancreatic adenocarcinoma progression via m6A-dependent alternative splicing in PANC-1 cells.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
METTL3 and METTL14, key components of the m6A methyltransferase complex, have been extensively studied in the context of various cancers. However, their roles in regulating alternative splicing in pancreatic cancer remain largely unexplored. In this study, we analyzed high-throughput RNA-seq data (GSE146806), alongside CLIP-seq datasets (GSE132306 and SRP163326), to investigate the molecular mechanisms underlying METTL3_14-mediated regulation. The results of differentially expressed genes (DEG) showed that that METTL3_14 knockdown significantly altered the expression of genes associated with canonical tumor-related pathways. Alternative splicing analysis identified METTL3_14-regulated alternatively spliced genes (RASGs) enriched in pathways such as protein processing in the endoplasmic reticulum, the spliceosome, and HIF-1 signaling, which are closely related to the progression of pancreatic cancer. Reanalysis of CLIP-seq data showed that METTL3_14 preferentially binds to the 3′UTR and coding sequences (CDS) regions. A total of 17 genes overlapped between DEGs and m6A-modified genes, while 59 genes overlapped with RASGs. Validation by qPCR confirmed significant regulatory effects on seven genes, especially EIF4A2, whose splicing was directly modulated by METTL3_14. These findings indicate that METTL3_14 may regulate gene expression and alternative splicing via m6A modifications in pancreatic cancer, particularly in pathways involved in transcription and DNA damage repair. This study provides novel mechanistic insights and potential targets for clinical diagnosis and treatment of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.